

AQILION

Helsingborg, Sweden, November 26, 2020

Press release

Aqilion presents Nomination Committee for the 2021 Annual General Meeting

The Nomination Committee for the 2021 Annual Meeting has been appointed and comprises the following members:

Helena Arcombe, appointed by the shareholder Länsförsäkringar Skåne
Christian Ewe, appointed by the shareholder LMK Forward AB
Linnea Höglund, appointed by the shareholder Länsförsäkringar Göteborg och Bohuslän
Malin Ruijsenaars, appointed by the shareholder Grenspecialisten AB

The members appoint the Chairman between themselves.

The Nomination Committee shall prepare proposals for the 2021 Annual General Meeting regarding the Chairman of the meeting, election of Board members and Chairman of the Board, the fees to be paid to the Board Chairman and the Board members, remuneration to the auditor and election of the auditor.

The Annual General Meeting of AQILION AB (publ) will be held on Thursday, June 10, 2021, at 05.00 p.m. (CET) in Helsingborg, Sweden.

To learn more about Aqilion, please visit the company's website www.aqilion.com.

For more information please contact:

Sarah Fredriksson, CEO, AQILION AB, + 46 (0)70 261 4575, sarah.fredriksson@aqilion.com

About Aqilion

Aqilion is a biotech company that focuses on developing new innovative treatments for diseases caused by chronic inflammation and dysfunctional immune reactions such as autoimmune diseases. The company is mainly active in the early phases of drug discovery, from idea to early clinical development.

Aqilion combines its experience from major pharmaceutical companies with the drive and entrepreneurship of small growth companies. With solid experience of business development in innovative biotech and pharmaceutical companies, Aqilion's experienced team and board have successfully shepherded drugs all the way from discovery to market.

AQILION AB (publ) is a public limited company headquartered in Helsingborg, Sweden.
www.aqilion.com